WM-Therapeutics
www.wm-therapeutics.comWMT targets the proteotoxic stress response / UPR to shut down cancer cell metabolism. This limits tumor autonomous growth and lowers intratumoral lactate to stimulate the immune system to re-attack the tumor. Our TOBY program is a combination of targeted chemotherapy with an immunooncology approach, casted into a single small molecule.
Read more
WMT targets the proteotoxic stress response / UPR to shut down cancer cell metabolism. This limits tumor autonomous growth and lowers intratumoral lactate to stimulate the immune system to re-attack the tumor. Our TOBY program is a combination of targeted chemotherapy with an immunooncology approach, casted into a single small molecule.
Read more
Country
City (Headquarters)
Heidelberg
Industry
Employees
11-50
Founded
2020
Social
Employees statistics
View all employeesPotential Decision Makers
Co - Founder , Executive Vice President Research
Email ****** @****.comPhone (***) ****-****Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Co Founder and Chairman of the Board
Email ****** @****.comPhone (***) ****-****Co - Founder , Chief Operations Officer , Sole Authorized Signature
Email ****** @****.comPhone (***) ****-****
Technologies
(9)
Reach decision makers at WM-Therapeutics
Free credits every month!
WM-Therapeutics FAQ
Heidelberg, Germany
Biotechnology Research
